Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.

Détails

Ressource 1Télécharger: BIB_B225879082EC.P001.pdf (2212.30 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_B225879082EC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.
Périodique
Frontiers in Immunology
Auteur(s)
Hebeisen M., Allard M., Gannon P.O., Schmidt J., Speiser D.E., Rufer N.
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
6
Pages
582
Langue
anglais
Notes
Publication types: Journal Article ; ReviewPublication Status: epublish
Résumé
Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides presented by the major histocompatibility complex (pMHC) on the surface of professional antigen-presenting cells and infected or malignant cells. The efficiency of T cell triggering critically depends on TCR binding to cognate pMHC, i.e., the TCR-pMHC structural avidity. The binding and kinetic attributes of this interaction are key parameters for protective T cell-mediated immunity, with stronger TCR-pMHC interactions conferring superior T cell activation and responsiveness than weaker ones. However, high-avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. Consequently, systematic assessment of T cell avidity can greatly help distinguishing protective from non-protective T cells. Here, we review novel strategies to assess TCR-pMHC interaction kinetics, enabling the identification of the functionally most-relevant T cells. We also discuss the significance of these technologies in determining which cells within a naturally occurring polyclonal tumor-specific T cell response would offer the best clinical benefit for use in adoptive therapies, with or without T cell engineering.
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/01/2016 17:33
Dernière modification de la notice
20/08/2019 16:20
Données d'usage